Advertisement
Screener

ELOXX PHARMACEUTICALS, INC. (ELOX) Financing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

ELOXX PHARMACEUTICALS, INC. Financing Cash Flow

ELOXX PHARMACEUTICALS, INC. (ELOX) reported Financing Cash Flow of $67.42 million for the 6-month period ending 2026-06-30, per its S-1 filed 2026-09-11.

Financial Statements › Cash Flow › Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-09-11

  • ELOXX PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $60.39M, a 3120.59% increase year-over-year.
  • ELOXX PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $7.03M.
  • ELOXX PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-06-30 was $1.88M.
  • ELOXX PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-03-31 was -$865.00K.
  • ELOXX PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $8.81M, a 82.65% decline from fiscal 2021.
  • ELOXX PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2021 was $50.79M.
  • ELOXX PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2020 was -$3.44M, a 107.35% decline from fiscal 2019.
  • ELOXX PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2019 was $46.80M, a 16.70% decline from fiscal 2018.
Period endNet Cash Provided by (Used in) Financing Activities 3 monthNet Cash Provided by (Used in) Financing Activities 3 month as first filedNet Cash Provided by (Used in) Financing Activities 6 monthNet Cash Provided by (Used in) Financing Activities 9 monthNet Cash Provided by (Used in) Financing Activities 12 monthNet Cash Provided by (Used in) Financing Activities 159 monthNet Cash Provided by (Used in) Financing Activities 162 monthNet Cash Provided by (Used in) Financing Activities 165 monthNet Cash Provided by (Used in) Financing Activities 168 monthNet Cash Provided by (Used in) Financing Activities 171 monthNet Cash Provided by (Used in) Financing Activities 174 monthNet Cash Provided by (Used in) Financing Activities 177 monthNet Cash Provided by (Used in) Financing Activities 180 monthNet Cash Provided by (Used in) Financing Activities 183 monthNet Cash Provided by (Used in) Financing Activities 186 monthNet Cash Provided by (Used in) Financing Activities 189 month
2026-06-30$60.39M
derived: S-1 6 month − S-1/A 3 month · filed 2026-09-11
$67.42M
S-1 · filed 2026-09-11
2026-03-31$7.03M
S-1/A · filed 2026-06-04
2025-12-31$11.00M
S-1 · filed 2026-09-11
2025-06-30$1.88M
derived: S-1 6 month − S-1/A 3 month · filed 2026-09-11
$1.01M
S-1 · filed 2026-09-11
2025-03-31-$865.00K
S-1/A · filed 2026-06-04
2024-12-31$3.44M
S-1 · filed 2026-09-11
2023-12-31-$1.68M
derived: S-1 12 month − 10-Q 9 month · filed 2026-09-11
$1.99M
derived: sum of 2 quarters · filed 2026-09-11
$3.42M
derived: sum of 3 quarters · filed 2026-09-11
-$4.08M
S-1 · filed 2026-09-11
2023-09-30$3.67M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13
$5.10M
derived: sum of 2 quarters · filed 2023-11-13
-$2.40M
10-Q · filed 2023-11-13
-$2.09M
derived: sum of 4 quarters · filed 2023-11-13
2023-06-30$1.43M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11
-$6.07M
10-Q · filed 2023-08-11
-$5.76M
derived: sum of 3 quarters · filed 2023-08-11
-$4.26M
derived: sum of 4 quarters · filed 2023-11-13
2023-03-31-$7.50M
10-Q · filed 2023-05-12
-$7.19M
derived: sum of 2 quarters · filed 2023-05-12
-$5.69M
derived: sum of 3 quarters · filed 2023-11-13
-$5.69M
derived: sum of 4 quarters · filed 2023-11-13
2022-12-31$312.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31
$1.81M
derived: sum of 2 quarters · filed 2023-11-13
$1.81M
derived: sum of 3 quarters · filed 2023-11-13
$8.81M
10-K · filed 2023-03-31
2022-09-30$1.50M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13
$1.50M
derived: sum of 2 quarters · filed 2023-11-13
$8.50M
10-Q · filed 2023-11-13
$8.34M
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11
$7.00M
10-Q · filed 2023-08-11
$6.84M
derived: sum of 3 quarters · filed 2023-08-11
$10.20M
derived: sum of 4 quarters · filed 2023-08-11
2022-03-31$7.00M
10-Q · filed 2023-05-12
$6.84M
derived: sum of 2 quarters · filed 2023-05-12
$10.20M
derived: sum of 3 quarters · filed 2023-05-12
$56.53M
derived: sum of 4 quarters · filed 2023-05-12
2021-12-31-$160.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31
$3.19M
derived: sum of 2 quarters · filed 2023-03-31
$49.53M
derived: sum of 3 quarters · filed 2023-03-31
$50.79M
10-K · filed 2023-03-31
2021-09-30$3.35M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10
$49.69M
derived: sum of 2 quarters · filed 2022-11-10
$50.95M
10-Q · filed 2022-11-10
$49.70M
derived: sum of 4 quarters · filed 2022-11-10
2021-06-30$46.33M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12
$47.59M
10-Q · filed 2022-08-12
$46.34M
derived: sum of 3 quarters · filed 2022-08-12
$45.09M
derived: sum of 4 quarters · filed 2022-08-12
2021-03-31$1.26M
10-Q · filed 2022-05-06
$10.00K
derived: sum of 2 quarters · filed 2022-05-06
-$1.24M
derived: sum of 3 quarters · filed 2022-05-06
-$1.69M
derived: sum of 4 quarters · filed 2022-05-06
2020-12-31-$1.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30
-$2.50M
derived: sum of 2 quarters · filed 2022-03-30
-$2.96M
derived: sum of 3 quarters · filed 2022-03-30
-$3.44M
10-K · filed 2022-03-30
2020-09-30-$1.25M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08
-$1.70M
derived: sum of 2 quarters · filed 2021-11-08
-$2.19M
10-Q · filed 2021-11-08
-$1.67M
derived: sum of 4 quarters · filed 2022-03-30
2020-06-30-$456.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16
-$939.00K
10-Q · filed 2021-08-16
-$420.00K
derived: sum of 3 quarters · filed 2022-03-30
-$536.00K
derived: sum of 4 quarters · filed 2022-03-30
2020-03-31-$483.00K
10-Q · filed 2021-05-07
$36.00K
derived: sum of 2 quarters · filed 2022-03-30
-$80.00K
derived: sum of 3 quarters · filed 2022-03-30
$32.22M
derived: sum of 4 quarters · filed 2022-03-30
2019-12-31$519.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30
$403.00K
derived: sum of 2 quarters · filed 2022-03-30
$32.70M
derived: sum of 3 quarters · filed 2022-03-30
$46.80M
10-K · filed 2022-03-30
2019-09-30-$116.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06
$32.18M
derived: sum of 2 quarters · filed 2020-11-06
$46.28M
10-Q · filed 2020-11-06
$48.79M
derived: sum of 4 quarters · filed 2021-03-12
2019-06-30$32.30M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07
$46.40M
10-Q · filed 2020-08-07
$48.91M
derived: sum of 3 quarters · filed 2021-03-12
$48.91M
derived: sum of 4 quarters · filed 2021-03-12
2019-03-31$14.10M
10-Q · filed 2020-05-08
$5.18M
10-Q · filed 2019-05-09
$16.61M
derived: sum of 2 quarters · filed 2021-03-12
$16.62M
derived: sum of 3 quarters · filed 2021-03-12
2018-12-31$2.51M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12
$2.52M
derived: sum of 2 quarters · filed 2021-03-12
$56.18M
10-K · filed 2021-03-12
2018-09-30$8.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06
$53.68M
10-Q · filed 2019-11-06
2018-06-30$53.67M
10-Q · filed 2019-08-07
2017-12-31$16.78M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-06
$18.28M
derived: sum of 2 quarters · filed 2020-03-06
$32.99M
derived: sum of 3 quarters · filed 2020-03-06
$37.95M
10-K · filed 2020-03-06
2017-09-30$1.50M
10-Q · filed 2017-11-14
$16.21M
derived: sum of 2 quarters · filed 2018-08-10
$21.17M
10-Q · filed 2018-11-08
2017-06-30$14.71M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10
$17.17M
10-Q · filed 2018-08-10
2017-03-31$2.46M
10-Q · filed 2018-05-10
2016-12-31$9.74M
10-K · filed 2019-03-14
2016-09-30$0.00
10-Q · filed 2017-11-14
2015-12-31$3.88M
10-K · filed 2018-03-16
2014-09-30$0.00
10-Q · filed 2014-11-14
$75.00K
derived: sum of 2 quarters · filed 2014-11-14
$1.87M
derived: sum of 3 quarters · filed 2014-11-14
$8.73M
derived: sum of 4 quarters · filed 2014-11-14
2014-06-30$75.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-09-29
$1.87M
derived: sum of 2 quarters · filed 2014-09-29
$8.73M
derived: sum of 3 quarters · filed 2014-09-29
$8.73M
10-K · filed 2014-09-29
2014-03-31$1.79M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-05-09
$8.65M
derived: sum of 2 quarters · filed 2014-05-09
$8.66M
10-Q · filed 2014-05-09
$9.76M
derived: sum of 4 quarters · filed 2014-11-14
$58.12M
10-Q · filed 2014-05-09
2013-12-31$6.86M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-02-14
$6.87M
10-Q · filed 2014-02-14
$7.97M
derived: sum of 3 quarters · filed 2014-11-14
$10.80M
derived: sum of 4 quarters · filed 2014-11-14
$56.33M
10-Q · filed 2014-02-14
2013-09-30$290.00
10-Q · filed 2014-11-14
$1.10M
derived: sum of 2 quarters · filed 2014-11-14
$3.94M
derived: sum of 3 quarters · filed 2014-11-14
$3.94M
derived: sum of 4 quarters · filed 2014-11-14
$49.47M
10-Q · filed 2013-11-14
2013-06-30$1.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-09-29
$3.94M
derived: sum of 2 quarters · filed 2014-09-29
$3.94M
derived: sum of 3 quarters · filed 2014-09-29
$4.03M
10-K · filed 2014-09-29
$49.47M
10-K · filed 2013-09-11
2013-03-31$2.84M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-05-09
$2.84M
derived: sum of 2 quarters · filed 2014-05-09
$2.93M
10-Q · filed 2014-05-09
$2.94M
derived: sum of 4 quarters · filed 2014-09-29
$48.36M
10-Q · filed 2013-05-15
2012-12-31$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-02-14
$94.18K
10-Q · filed 2014-02-14
$103.22K
derived: sum of 3 quarters · filed 2014-09-29
$2.85M
derived: sum of 4 quarters · filed 2014-09-29
$45.53M
10-Q · filed 2013-02-14
2012-09-30$94.18K
10-Q · filed 2013-11-14
$103.22K
derived: sum of 2 quarters · filed 2014-09-29
$2.85M
derived: sum of 3 quarters · filed 2014-09-29
$2.87M
derived: sum of 4 quarters · filed 2014-09-29
$45.53M
10-Q · filed 2012-11-14
2012-06-30$9.04K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-09-29
$2.75M
derived: sum of 2 quarters · filed 2014-09-29
$2.78M
derived: sum of 3 quarters · filed 2014-09-29
$3.23M
10-K · filed 2014-09-29
$45.43M
10-K/A · filed 2012-10-26
2012-03-31$2.75M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-05-15
$2.77M
derived: sum of 2 quarters · filed 2013-05-15
$3.22M
10-Q · filed 2013-05-15
$3.24M
derived: sum of 4 quarters · filed 2013-09-11
$45.42M
10-Q · filed 2012-05-14
2011-12-31$22.12K
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-02-14
$473.22K
10-Q · filed 2013-02-14
$495.28K
derived: sum of 3 quarters · filed 2013-09-11
$1.99M
derived: sum of 4 quarters · filed 2013-09-11
$42.68M
10-Q · filed 2012-02-14
2011-09-30$451.10K
10-Q · filed 2012-11-14
$473.16K
derived: sum of 2 quarters · filed 2013-09-11
$1.96M
derived: sum of 3 quarters · filed 2013-09-11
$42.66M
10-Q · filed 2011-11-14
2011-06-30$22.07K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-09-11
$1.51M
derived: sum of 2 quarters · filed 2013-09-11
$1.66M
10-K · filed 2013-09-11
2011-03-31$1.49M
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-05-14
$1.64M
10-Q · filed 2012-05-14
2010-12-31$149.28K
10-Q · filed 2012-02-14
2010-06-30$12.15M
10-K/A · filed 2012-10-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
MiNK Therapeutics, Inc. (INKT)United States$0.063B-5.37
BioStem Technologies, Inc. (BSEM)United States$0.069B
CHAMPIONS ONCOLOGY, INC. (CSBR)United States$0.070B-68.02
EXOZYMES INC. (EXOZ)United States$0.058B
BioAtla, Inc. (BCAB)United States$0.058B-0.21
ImageneBio, Inc. (IMA)United States$0.056B-1.31
Kalaris Therapeutics, Inc. (KLRS)United States$0.073B-2.19
Inmune Bio, Inc. (INMB)United States$0.056B-2.48
Vaxart, Inc. (VXRT)United States$0.080B3.84
Tevogen Inc. (TVGN)United States$0.049B